Loading...
StocksRunner logo
 
 
Axonics
50.22
-2.69%
 
AXNX Axonics
Last Price
Change
50.22
 
-2.69%
 
 
 

 
Sentiment
 
 

58.76

57.7

61.94

56.64

 
 
1m
3m
6m
1y
 

Summary

  Login to display Axonics (AXNX) recommendation from the last 90 days from financial news and social media.
 

Strengths

Rewards

 Upgraded on attractively valued

Rewards

 Earnings are forecast to grow

Rewards

 Outperform the market

Rewards

 Trading below its fair value

 
 

Risk Level

 
StocksRunner
 

Axonics (AXNX) has Moderate Risk Level

Click here to check what is your level of risk

 

Analysts Opinion

Click on the category for more information
 
 

Earnings

×
 

Earnings

3.00
 

StocksRunner

 Reported a weak earnings

StocksRunner

 Above analyst estimates

 
 

Rating

×
 

Rating

5.00
 

StocksRunner

 Upgraded on attractively valued

 

Momentum

×
 

Momentum

4.00
 

StocksRunner

 Has been gaining momentum

 

Activity

×
 

Activity

NA
 
 

Future

×
 

Future

4.60
 

StocksRunner

 Earnings are forecast to grow

StocksRunner

 Outperform the market

StocksRunner

 Trading below its fair value

 
 

Analysts Opinion

Analysts opinion is positive and also has improved from the past 3 months

 

Street Consensus

Buy
Opinion
Trend
Score
Potential
Score
 
92%
100%
100%
100%
 
On Track
On Track
On Track
 

Street Opinion 

Street view is extremely ish and have positive views on the near-term outlook

 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
Positive vs Negative
 
92%
8%
Positive
Negative
12 out of 13
events present
1 out of 13
events present
 

 
Events Calendar
Click for more information
 
May
S
M
T
W
T
F
S
June
S
M
T
W
T
F
S
 
Highlights
Last
Modify
Closing
Price
%
Change

 
Buy Rating
2 Weeks Ago
51.55
-0.12%
 
Buy Rating
3 Weeks Ago
54.15
-1.66%
 
Buy Rating
2 Month Ago
52.99
-9.65%
 
Strong Earnings
2 Month Ago
58.76
+2.26%
 
Top Headlines

cl king initiates coverage of axonics (axnx) with buy recommendation. fintel reports that on may 23 2023 cl king initiated coverage of axonics (nasdaq:axnx) with a buy recommendation.

Tue May 23, 2023

Rating

rbc capital reiterates axonics (axnx) outperform recommendation. fintel reports that on may 15 2023 rbc capital reiterated coverage of axonics (nasdaq:axnx) with a outperform recommendation.

Tue May 16, 2023

Potential

needham reiterates axonics (axnx) buy recommendation. fintel reports that on may 12 2023 needham reiterated coverage of axonics (nasdaq:axnx) with a buy recommendation.

Fri May 12, 2023

Rating

axonics: attractive strong growth profile.

Fri May 12, 2023

Potential

axonics: q1 fall provides great entry point.

Thu May 4, 2023

Momentum

rbc capital reiterates axonics (axnx) outperform recommendation. fintel reports that on may 2 2023 rbc capital reiterated coverage of axonics (nasdaq:axnx) with a outperform recommendation.

Wed May 3, 2023

Potential

axonics q1 soars past estimates: analysts say annual sales outlook is conservative. ) reported a q1 eps loss of $(0.19) better than the consensus of $(0.29). sales increased 46% y/y to $70.65 million beating the

Tue May 2, 2023

Momentum

needham maintains axonics (axnx) buy recommendation. fintel reports that on may 2 2023 needham maintained coverage of axonics (nasdaq:axnx) with a buy recommendation.

Tue May 2, 2023

Rating

axonics modulation technologies (axnx) reports q1 loss tops revenue estimates. axonics modulation technologies (axnx) came out with a quarterly loss of $0.19 per share versus the zacks consensus estimate of a loss of $0.34. this compar

Mon May 1, 2023

Earnings
Earnings

 
 
 
StocksRunner

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our daily AXNX alerts

Enter your email to receive daily alerts

 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

 
Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

 
Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
About Us

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
StocksRunner

StocksRunner

Get the pulse of the market

 
StocksRunner

AXNX Axonics

Last Price
50.22
Change
-2.69%
 

Summary

  Login to display Axonics (AXNX) recommendation from the last 90 days from financial news and social media.

 
 
58.76
57.7
61.94
56.64
 
 
1m
3m
6m
1y
 
Sentiment

Strengths

Rewards

 Upgraded on attractively valued

Rewards

 Earnings are forecast to grow

Rewards

 Outperform the market

Rewards

 Trading below its fair value

 
 
 
 
Street Consensus
 
Buy
Opinion
Trend
Score
Potential
Score
 
100%
100%
100%
On Track
On Track
On Track
 
92%
8%
Positive
Negative
12 out of 13
events present
1 out of 13
events present
 

Street Opinion

Street view is extremely ish and have positive views on the near-term outlook

 
 
Analysts Opinion
Hover the category for more information
 
 

Earnings

×
 

Earnings

3.00
 

StocksRunner

 Reported a weak earnings

StocksRunner

 Above analyst estimates

 
 

Rating

×
 

Rating

5.00
 

StocksRunner

 Upgraded on attractively valued

 

Momentum

×
 

Momentum

4.00
 

StocksRunner

 Has been gaining momentum

 

Activity

×
 

Activity

NA
 
 

Future

×
 

Future

4.60
 

StocksRunner

 Earnings are forecast to grow

StocksRunner

 Outperform the market

StocksRunner

 Trading below its fair value

 
 

Analysts Opinion

Analysts opinion is positive and also has improved from the past 3 months

 
 
 
 
 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
 
Risk Level
 
StocksRunner
 

Axonics (AXNX) has Moderate Risk Level.  Click here to check what is your level of risk

 
 
 

Events Calendar

Hover for information

 
May
 
S
M
T
W
T
F
S
 
June
 
S
M
T
W
T
F
S
 
 
 
 
Highlights
Last
Modify
Closing
Price
%
Change

 
Buy Rating
2 Weeks Ago
51.55
-0.12%
 
Buy Rating
3 Weeks Ago
54.15
-1.66%
 
Buy Rating
2 Month Ago
52.99
-9.65%
 
Strong Earnings
2 Month Ago
58.76
+2.26%
 
 
 
StocksRunner

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our daily AXNX Alerts

Enter your email to receive daily alerts

 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
 
 
 

Top Headlines